With our previous Longevity Consortium (LC) support, we brought together four extreme longevity (EL) studies that have agreed to share their individual level genetic and phenotypic data for more powerful genetic association analyses of human EL. Working closely with the other LC projects and cores, we will utilize these and developed unique resources to achieve 3 primary goals: (1) discover additional rare/uncommon EL and compression of morbidity genetic variants; (2) analyze gene expression profiles associated with EL-genetic variants to be used to search for healthy aging therapeutics; (3) strategically enroll new participants in the New England Centenarian Study (NECS) to provide biomaterial and phenotypic and genetic data for discovery- phase and validation/replication and follow-up experiments for this and other LC projects and cores. Specifically, in Aim 1 (Discovery) we propose to conduct a genome-wide association mega-analysis of EL and selected sub-phenotypes using data from 2,070 centenarians and 6,259 controls aggregated from the 4 longevity studies. The Japanese Centenarian Study, Health and Retirement Study, the Danish Longevity Study, and new data from Aim 3 will provide independent replication.
In Aim 2 (Translation) we will link genetic data to whole blood gene expression data generated from 400 Long Life Family Study (LLFS) subjects, ages ranging from 50 to 110 years. These data will be used to generate expression quantitative trait loci (eQTLs) and gene/protein sets associated with significant eQTLs that are also associated with EL. Bioinformatics analyses in conjunction with the Chemoinformatics core will be aimed at discovering biomolecules and existing drugs that mimic the effects of the EL-associated mechanisms naturally occurring in people with EL genotypes. Mediation analysis will be used to investigate the joint effects of EL-promoting variants and their associated molecular signatures on age of onset of dementia, diabetes, cardiovascular disease, stroke, and cognitive impairment. These analyses will characterize the healthy aging patterns that might be enabled by the candidate compounds.
In Aim 3 (discovery, validation and follow-up) we will identify 10-15 already enrolled families with informative patterns of familial EL from the collaborating EL studies. We will enroll additional critical family members from these families (e.g. siblings, cousins, etc) and use next generation whole genome sequencing to discover novel, rare EL-variants and to perform fine mapping of variants discovered in Aim 1. Newly enrolled subjects from these families as well as non-familial 103+ year olds will also provide data and biomaterial for planned studies by the other LC projects and cores. Through these aims and in collaboration with other LC projects and cores, the Centenarians Project will build on resources and findings from the previous cycle of the LC to discover new genetic variants associated with EL, integrate genetic and molecular data to identify targets for healthy-aging therapeutics, and generate unique biomaterial and data resources for work described by the other LC projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AG023122-11A1
Application #
9632494
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2018-09-30
Budget End
2019-05-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
California Pacific Medical Center Research Institute
Department
Type
DUNS #
071882724
City
San Francisco
State
CA
Country
United States
Zip Code
94107
Brown, Abigail K; Webb, Ashley E (2018) Regulation of FOXO Factors in Mammalian Cells. Curr Top Dev Biol 127:165-192
Zeng, Yi; Nie, Chao; Min, Junxia et al. (2018) Sex Differences in Genetic Associations With Longevity. JAMA Netw Open 1:
Schork, Nicholas J; Raghavachari, Nalini; Workshop Speakers and Participants (2018) Report: NIA workshop on translating genetic variants associated with longevity into drug targets. Geroscience 40:523-538
Ding, Kuan-Fu; Finlay, Darren; Yin, Hongwei et al. (2018) Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients. Front Genet 9:228
Ding, Kuan-Fu; Petricoin, Emanuel F; Finlay, Darren et al. (2018) Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. Oncotarget 9:5044-5057
Perls, Thomas T (2017) Male Centenarians: How and Why Are They Different from Their Female Counterparts? J Am Geriatr Soc 65:1904-1906
Pickering, Andrew M; Lehr, Marcus; Gendron, Christi M et al. (2017) Mitochondrial thioredoxin reductase 2 is elevated in long-lived primate as well as rodent species and extends fly mean lifespan. Aging Cell 16:683-692
Ding, Kuan-Fu; Finlay, Darren; Yin, Hongwei et al. (2017) Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget 8:27786-27799
Sebastiani, Paola; Bae, Harold; Gurinovich, Anastasia et al. (2017) Limitations and risks of meta-analyses of longevity studies. Mech Ageing Dev 165:139-146
Sebastiani, Paola; Thyagarajan, Bharat; Sun, Fangui et al. (2017) Biomarker signatures of aging. Aging Cell 16:329-338

Showing the most recent 10 out of 202 publications